Science

Michael Hofman: 18F-CETO for primary aldosteronism

Michael Hofman/X

Feb 4, 2025, 17:03

Michael Hofman: 18F-CETO for primary aldosteronism

Michael Hofman, Nuclear Medicine Physician at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by Daniel Gillett et al. published in Journal of Nuclear Medicine:

“18F-CETO for primary aldosteronism: a promising adrenal gland PET/C T – can distinguish aldosterone-producing adenomas from normal adrenal tissue, thereby improving the evaluation and management of primary aldosteronism.

Very nice work from Daniel Gillett.”

“A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism”

Authors: Daniel Gillett, Russell Senanayake, James MacFarlane, Franklin Aigbirhio, Mark Gurnell et al.

Michael Hofman: 18F-CETO for primary aldosteronism

More posts featuring Michael Hofman.

18F-CETO aldosteronism cancer Daniel Gillett Franklin Aigbirhio James MacFarlane Mark Gurnell Michael Hofman OncoDaily Oncology primary aldosteronism Russell Senanayake

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage